[go: up one dir, main page]

EP1546132A1 - Derives de pyrazole utilises en tant qu'inhibiteurs de la transcriptase inverse - Google Patents

Derives de pyrazole utilises en tant qu'inhibiteurs de la transcriptase inverse

Info

Publication number
EP1546132A1
EP1546132A1 EP03798326A EP03798326A EP1546132A1 EP 1546132 A1 EP1546132 A1 EP 1546132A1 EP 03798326 A EP03798326 A EP 03798326A EP 03798326 A EP03798326 A EP 03798326A EP 1546132 A1 EP1546132 A1 EP 1546132A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
alkyl
conr
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03798326A
Other languages
German (de)
English (en)
Inventor
Oscar Pfizer Global Research & Development BARBA
L. H. Pfizer Global Research & Development JONES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barba Oscar
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0222374A external-priority patent/GB0222374D0/en
Priority claimed from GB0223356A external-priority patent/GB0223356D0/en
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of EP1546132A1 publication Critical patent/EP1546132A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • R 1 is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR 5 , -CONR 5 R 5 , -S0 2 NR 5 R 5 , -NR 5 SO 2 R 5 , -OR 5 , OR 11 , -NR 5 R 5 ,
  • each R 6 is independently either H, C C 6 alkyl or C 3 -C cycloalkyl
  • R 9 is azetidinyl, tetrahydropyrrolyl, piperidinyl, azepinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepinyl, morpholinyl, piperazinyl or diazepinyl, each being optionally substituted by oxo, d-C ⁇ alkyl, C- 3 -C 7 cycloalkyl, -SO 2 R 5 , -CONR 5 R 5 , -COOR 5 , -CO-(d-C 6 alkylene)-OR 5 or -COR 5 and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR 5 , -NR 5 R 5 , -NR 5 COR 5 , -NR 5 COOR 5 , -NR 5 CONR 5 R 5 , -NR 5 S0 2 R 5 or
  • R 2 is optionally substituted C C ⁇ alkyl
  • R 2 is optionally substituted C C ⁇ alkyl
  • Suitable alkylating agents include bromoacetonitrile, ethyl
  • the compounds of the invention can be administered alone, but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • Such solid pharmaceutical compositions may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably com, potato or tapioca starch), disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
  • excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably com, potato or tapioca starch), disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates
  • reverse transcriptase inhibitors such as abacavir, adefovir, didanosine, lamivudine, stavudine, zalcitabine and zidovudine;

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés de pyrazole représentés par la formule (I) ou des sels, des solvates, ou des dérivés pharmaceutiquement acceptables de ceux-ci; dans la formule, R' à R4 sont tels que définis dans la description. Cette invention concerne également des procédés de préparation, des produits intermédiaires utilisés lors de la préparation de ces dérivés de pyrazole, des compositions les contenant ainsi que les utilisations de tels dérivés. Les composés décrits dans cette invention se fixent à la transcriptase inverse, et sont des modulateurs, plus spécifiquement des inhibiteurs. Ces composés sont utilisés pour le traitement de divers troubles, y compris ceux impliquant l'inhibition de la transcriptase inverse. Entre autres troubles concernés, figurent ceux causés par le virus de l'immunodéficience humaine (VIH) et des rétrovirus génétiquement associés, tels que le syndrome d'immunodéficience acquise (SIDA).
EP03798326A 2002-09-26 2003-09-15 Derives de pyrazole utilises en tant qu'inhibiteurs de la transcriptase inverse Withdrawn EP1546132A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0222374A GB0222374D0 (en) 2002-09-26 2002-09-26 Chemical compounds
GB0222374 2002-09-26
GB0223356A GB0223356D0 (en) 2002-10-08 2002-10-08 Chemical compounds
GB0223356 2002-10-08
PCT/IB2003/004158 WO2004029042A1 (fr) 2002-09-26 2003-09-15 Derives de pyrazole utilises en tant qu'inhibiteurs de la transcriptase inverse

Publications (1)

Publication Number Publication Date
EP1546132A1 true EP1546132A1 (fr) 2005-06-29

Family

ID=32044462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03798326A Withdrawn EP1546132A1 (fr) 2002-09-26 2003-09-15 Derives de pyrazole utilises en tant qu'inhibiteurs de la transcriptase inverse

Country Status (7)

Country Link
EP (1) EP1546132A1 (fr)
JP (1) JP2006504803A (fr)
AU (1) AU2003260908A1 (fr)
BR (1) BR0314709A (fr)
CA (1) CA2497333A1 (fr)
MX (1) MXPA05003195A (fr)
WO (1) WO2004029042A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101401811B1 (ko) 2006-08-16 2014-05-29 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 저해제
KR20100039348A (ko) 2007-06-22 2010-04-15 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역 전사효소 억제제로서 우레아 및 카바메이트 유도체
CN101903382B (zh) 2007-12-21 2012-11-28 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
EA202091835A1 (ru) 2018-01-31 2020-10-20 Янссен Сайенсиз Айрлэнд Анлимитед Компани Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
MX2020011200A (es) 2018-04-23 2020-11-13 Janssen Sciences Ireland Unlimited Co Compuestos heteroaromaticos que tienen actividad contra vrs.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419391A (en) * 1965-05-24 1968-12-31 Eastman Kodak Co Silver halide color photography utilizing magenta-dye-forming couplers
DK169672B1 (da) * 1985-05-20 1995-01-09 Mitsubishi Chem Ind Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater
JPH0667838B2 (ja) * 1985-12-25 1994-08-31 三菱化成株式会社 過酸化脂質生成抑制剤
JPH01125379A (ja) * 1987-11-10 1989-05-17 Sumitomo Chem Co Ltd 置換ピラゾール誘導体、その製造方法およびそれを有効成分とする農園芸用殺菌剤
AU3553489A (en) * 1988-05-09 1989-11-29 Beecham Group Plc Novel compounds and treatment
JPH03141276A (ja) * 1989-10-24 1991-06-17 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
US5189040A (en) * 1990-05-28 1993-02-23 Sumitomo Chemical Company, Limited Pyrazole derivatives, method for producing the same and agricultural and/or horticultural fungicides containing the same as active ingredient
US5447831A (en) * 1993-10-19 1995-09-05 Eastman Kodak Company Photographic element employing hue correction couplers
US6365334B1 (en) * 1993-10-22 2002-04-02 Eastman Kodak Company Photographic elements containing aryloxypyrazolone couplers and sulfur containing stabilizers
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004029042A1 *

Also Published As

Publication number Publication date
CA2497333A1 (fr) 2004-04-08
AU2003260908A1 (en) 2004-04-19
WO2004029042A1 (fr) 2004-04-08
MXPA05003195A (es) 2005-06-08
BR0314709A (pt) 2005-07-26
JP2006504803A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
US6933312B2 (en) Pyrazole derivatives
KR100569324B1 (ko) Ｈｉｖ 치료용 피라졸 유도체
EP1551828B1 (fr) Derives de pyrazole
US7220772B2 (en) Pyrazole derivatives
EP1546132A1 (fr) Derives de pyrazole utilises en tant qu'inhibiteurs de la transcriptase inverse
EP1556381B1 (fr) Pyrazole amides destines au traitement d'infections par le vih
EP1542679B1 (fr) Derives de 4-(3,5-dicyanophenoxy)pyrazole utilises comme modulateurs de la transcriptase inverse dans le traitement, entre autres, du vih
EP1556359B1 (fr) Derives de pyrazole et utilisation de ceux-ci comme agents therapeutiques destines aux maladies induites par le vih
US7230025B2 (en) Pyrazole derivatives
US20040132793A1 (en) Pyrazole derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BARBA, OSCAR

Owner name: PFIZER LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BARBA, OSCAR

Owner name: PFIZER LIMITED

17Q First examination report despatched

Effective date: 20091124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100331